New Delhi, Aug 24: The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study. "Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted…

India's first mRNA-based Covid-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for phase 2/3 clinical trails, the department of biotechnology (DBT) said on Tuesday. The Pune-based biotechnology company had submitted the interim clinical data of the vaccine’s phase 1 study to the central drugs standard control organisation, it said.…

Emcure Pharmaceuticals, one of the leading pharma companies in India, has filed papers with markets regulator SEBI to raise funds via an initial public offer (IPO). It will list the shares on NSE and BSE.

The company is looking to raise up to Rs 4,500-5,000 crore in an offer that would consist of a fresh issue of shares and an offer for sale (OFS). The fresh issue is likely to be worth Rs 1,100 crore whereas the offer for sale would be worth Rs 3,400 crore. Promoters and private equity…

Second-generation entrepreneur Satish Mehta started Emcure Pharmaceuticals decades before ‘Made in India’ or ‘Build in India’ became catchphrases.

Founded in 1981 as a contract manufacturer for multinational pharma giants, the Pune-based firm went on to develop and sell its own branded generic formulations across 70 countries, and become one of the leading companies in the sector. …

In 2007, within two years of the merger of Dubai-based Emaar and Shravan Gupta-owned MGF, a British Virgin Islands (BVI) firm invested USD 2 million in the joint venture, according to the Pandora Papers.

Gupta was the beneficial owner of a company in BVI where its Finance Ministry issued two notices after his name surfaced in the HSBC Bank (Geneva) list of Indian account holders.…

Bain Capital-backed Emcure Pharmaceuticals filed preliminary papers with capital markets regulator SEBI to raise funds through an initial share sale.

The initial public offering comprises fresh issuance of equity shares worth ₹1,100 crore and an offer of sale of over 1.8 crore (1,81,68,356) shares by promoters and existing shareholders, according to the draft red herring prospectus (DRHP).…

India’s first domestically developed mRNA-based Covid-19 vaccine candidate has been found safe in its interim Phase 1 clinical trials, and the national drugs regulator has granted approval to its maker, Pune-based Gennova Biopharmaceuticals, to begin Phase 2/3 trials, the Union ministry of science and technology said on Tuesday.

The development of HGCO19, the country’s first vaccine based on messenger-RNA (mRNA) technology, is a key step in India’s target of vaccinating all adults by…

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study.

“Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the…

In a significant development towards India’s vaccination efforts, the Drug Controller General of India, has approved Phase II and Phase III study protocols for HGCO19, India’s first mRNA-based COVID-19 vaccine, developed by Gennova Biopharmaceuticals (Gennova).

Gennova, the subsidiary of Pune based Emcure Pharmaceuticals Limited had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO), the Government of India's National…

Emcure Pharmaceuticals Limited, one of India's biggest pharmaceutical businesses, has filed its Draft Red Hearing Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise funds through an IPO (IPO).

The offer included a fresh issue of up to Rs 1,100 crores in shares and an offer for sale of up to 18,168,356 shares. Promoters and Bain Capital, a private equity firm, are among those who will sell their stock. A pre-IPO placement of up to Rs 200…

Emcure Pharmaceuticals Limited, pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas, has filed its Draft Red Hearing Prospectus with market regulator Securities and Exchange Board of India.

News reports had earlier mentioned that the Bain Capital-backed Emcure firm would come out with a Rs 4,000 crore in August.…

Emcure claims to be an R&D driven company with a differentiated product portfolio that includes orals, injectables and biologics, as well as an mRNA platform through which it is currently developing a COVID-19 vaccine, which has enabled it to reach a range of target markets across over 70 countries with a strong presence in Europe and Canada.…

The mRNA-based vaccine has been developed in partnership with Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC).

•Gennova Biopharmaceuticals Ltd., which is a Pune-based biotechnology company, had submitted the interim clinical data of the Phase I study to the Central Drugs Standard Control Organisation (CDSCO) and the Centre's National Regulatory Authority (NRA).

•The Vaccine Subject Expert Committee had then reviewed the interim…

Emcure Pharmaceuticals Limited, one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas, has filed its Draft Red Hearing Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise funds via initial public offering (IPO). …

Emcure Pharmaceuticals Limited has filed its draft IPO (Initial Public Offering) papers with capital markets regulator SEBI. The company is looking to raise more than Rs 1,100 crore through the public issue which will include a fresh issue of equity shares upto Rs 1,100 crore and an offer for sale (OFS) of 18,168,356 equity shares by existing shareholders, including promoters of the company. Overall the issue size would be higher than Rs 1,100 crore. In terms of sales, Emcure Pharmaceuticals…

India’s first mRNA vaccine against coronavirus – developed by Pune-based Gennova Biopharmaceuticals Ltd (part of Emcure group of companies) – has been found to be safe and it has been given the go-ahead from the Drugs Controller General of India (DCGI) to move into Phase II and III of clinical trials.

The firm had submitted the interim clinical data of its Phase I trial to the Central Drugs Standard Control Organisation (CDSCO), the Government of India’s National Regulatory…

India’s indigenously-developed mRNA vaccine has received regulatory nod for Phase II and III clinical trials, said an official statement on Tuesday.

This is the second mRNA vaccine to reach advanced trial stage, after Moderna’s mRNA vaccine, which is already in use in the US and several other countries.

The vaccine developed by Pune-based Gennova Biopharmaceuticals was approved for further trials by the Drugs Controller General of India (DCGI), as the apex regulatory body found…

Pune-based Emcure Pharmaceuticals Ltd. filed its draft red herring prospectus with the Securities and Exchanges Board of India on Thursday. The company is looking to raise Rs 1,100 crore through a fresh issue of equity shares and also conduct an offer for sale of 1.82 crore shares owned by promoters, promoter group and other investors.…

Pune-based Emcure Pharmaceuticals Limited, the 12th largest pharmaceutical company in India, has filed its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) for its initial public offering (IPO). Market sources say the company is planning an IPO for about Rs 4,000 crore, though it hasn't finalised the date of launching the issue.

The IPO will include a fresh issue of equity shares aggregating up to Rs 1,100 crores and an offer for…

BENGALURU, Aug 24 (Reuters) – India has approved further clinical trials for its first local mRNA-based COVID-19 vaccine developed by Gennova Biopharmaceuticals Ltd, the government said on Tuesday, after the injection was found to be safe and effective in an early stage study.

Gennova is one of the few pharmaceutical companies worldwide – including Moderna Inc and Pfizer Inc – that use mRNA technology in their coronavirus vaccine.…